← Back to Patent Explorer
US4470975A Expired / Lapsed US ⏱️ 0.0 years remaining

Method and composition for the elimination of water from an animal body

Assignee: HB BIOTECHNOLOGIES Corp
•
Filing: 1977-10-21
•
Granted: 1984-09-11
•
Expires: 1997-10-21
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract It has been found that certain insoluble hydrophilic cross-linked polysaccharides are useful pharmaceutical agents in diverting water elimination from the renal route to the gastrointestinal route, and removing excess water from the body by the gastrointestinal route. These properties are of specific therapeutic value in the treatment of edema, water intoxication in chronic renal failure, in reducing the frequency of hemodialysis, and in the treatment of other forms of fluid retention such as congestive heart failure, cirrhosis of the liver, and other disorders associated with refractory swelling. Sephadex-brand insoluble hydrophilic, cross-linked dextrans are preferred in the practice of the invention.

Inventors

  • 👤 Hillard Berger, deceased
  • 👤 W. Gordon Walker

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-24 06:12
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 62 words
A method of treating edema in a host in need of such treatment because of renal failure which comprises orally administering to said host an effective amount of a water-insoluble hydrophilic, cross-linked polysaccharide which is capable of absorbing water in the lumen of the gastrointestinal tract and discharging the thus bound water by passage from the alimentary canal in the normal way.
Claim 2
Independent Claim 62 words
A method of treating edema in a host in need of such treatment because of renal failure which comprises orally administering to said host an effective amount of a water-insoluble hydrophilic, cross-linked polysaccharide which is capable of absorbing water in the lumen of the gastrointestinal tract and discharging the thus bound water by passage from the alimentary canal in the normal way.
Claim 3
Dependent Claim 104 words
A method according to claim 1 wherein said polysaccharide consists essentially of a copolymerization product in a gel grain form comprising a 3-dimensional macroscopic carbohydrate network, obtained from a neutral carbohydrate selected from the group consisting of dextran, sorbitol, starch, hydroxyethyl cellulose, dextrin, and sucrose and a bifunctional organic substance selected from the group consisting of epichlorohydrin, dichlorohydrin, diepoxybutane, bisepoxypropyl ether, ethylene glycol-bis-epoxypropyl ether, and 1,4-butan-diol-bis-epoxypropyl ether, bonded together by ether bridges of the general type --O--X--O-- wherein X representa an aliphatic radical containing from 3 to 10 carbon atoms, the said copolymerization product being water-insoluble but being capable of absorbing water with swelling.
Claim 4
Dependent Claim 77 words
A method according to claim 1 wherein said polysaccharide is a copolymerization product in gel grain form comprising a 3-dimensional macroscopic network of dextran substances, built-up of chains of mainly alpha-1,6-glucosidically bonded glucose residues, bonded together by ether bridges of the general type --R--O--X--O--R--, wherein R represents the dextram substances and X is an aliphatic radical containing from 3 to 10 carbon atoms, the said copolymerization product being water-insoluble but being capable of absorbing water with swelling.
Claim 5
Independent Claim 61 words
A method for treating obesity which comprises administering orally to a host in need of such treatment an effective amount of a water-insoluble hydrophilic, cross-linked polysaccharide which is capable of absorbing water with swelling in the lumen of the gastrointestinal tract, said oral administration being effective to eliminate the bound water via the gastro-intestinal route rather than by the renal route.
Claim 6
Independent Claim 61 words
A method for treating obesity which comprises administering orally to a host in need of such treatment an effective amount of a water-insoluble hydrophilic, cross-linked polysaccharide which is capable of absorbing water with swelling in the lumen of the gastrointestinal tract, said oral administration being effective to eliminate the bound water via the gastro-intestinal route rather than by the renal route.
Claim 7
Independent Claim 37 words
A method for treating edema in a mammal in need of such treatment which comprises administering orally to said mammal an effective amount of a water-insoluble hydrophilic, cross-linked polysaccharide which is capable of absorbing water with swelling.
Claim 8
Independent Claim 37 words
A method for treating edema in a mammal in need of such treatment which comprises administering orally to said mammal an effective amount of a water-insoluble hydrophilic, cross-linked polysaccharide which is capable of absorbing water with swelling.
Claim 9
Independent Claim 37 words
A method for treating obesity in a mammal in need of such treatment which comprises administering orally to said mammal an effective amount of a water-insoluble hydrophilic, cross-linked polysaccharide which is capable of absorbing water with swelling.
Claim 10
Independent Claim 37 words
A method for treating obesity in a mammal in need of such treatment which comprises administering orally to said mammal an effective amount of a water-insoluble hydrophilic, cross-linked polysaccharide which is capable of absorbing water with swelling.
Claim 11
Independent Claim 53 words
A method for reducing the frequency of dialysis to a mammal in need of such treatment because of renal failure which comprises orally administering to said mammal an effective amount of a water-insoluble hydrophilic, cross-linked polysaccharide which is capable of absorbing water with swelling, and eliminating the bound water through the gastrointestinal route.
Claim 12
Independent Claim 53 words
A method for reducing the frequency of dialysis to a mammal in need of such treatment because of renal failure which comprises orally administering to said mammal an effective amount of a water-insoluble hydrophilic, cross-linked polysaccharide which is capable of absorbing water with swelling, and eliminating the bound water through the gastrointestinal route.

References Cited (Backward Citations)

GB854715A Cited
US3624209A Cited
US3627872A Cited
US4076930A Cited
US3865807A Cited
US3934007A Cited
US3962429A Cited
US3983232A Cited
US4002173A Cited
US4070460A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1987-09-11 1988-03-12 1988-09-11 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1991-09-11 1992-03-12 1992-09-11 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1995-09-11 1996-03-12 1996-09-11 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag